Excitatory amino acid antagonists for acute stroke

Muir, Keith W.; Lees, Kennedy R.

doi:10.1002/14651858.cd001244

Cited by 86 publications

(60 citation statements)

References 68 publications

(1 reference statement)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…529 A systematic review of the trials testing these medications found no improvements in rates of either death or favorable outcomes with treatment. 530 Neither fosphenytoin nor sipatrigine has demonstrated effectiveness in treatment of acute stroke. 531,532 Repinotan, a serotonin agonist, has shown some promise in preliminary studies.…”

Section: Neuroprotective Agentsmentioning

confidence: 99%

Guidelines for the Early Management of Adults With Ischemic Stroke

Adams¹,

Zoppo²,

Alberts³

et al. 2007

Circulation

1,062

745

View full text Add to dashboard Cite

Purpose-Our goal is to provide an overview of the current evidence about components of the evaluation and treatment of adults with acute ischemic stroke. The intended audience is physicians and other emergency healthcare providers who treat patients within the first 48 hours after stroke. In addition, information for healthcare policy makers is included. Key Words: AHA Scientific Statements Ⅲ emergency medical services Ⅲ stroke Ⅲ acute cerebral infarction Ⅲ tissue plasminogen activator †Deceased. The American Heart Association makes every effort to avoid any actual or potential conflicts of interest that may arise as a result of an outside relationship or a personal, professional, or business interest of a member of the writing panel. Specifically, all members of the writing group are required to complete and submit a Disclosure Questionnaire showing all such relationships that might be perceived as real or potential conflicts of interest. Methods-Members

show abstract

Section: Neuroprotective Agentsmentioning

confidence: 99%

Guidelines for the Early Management of Adults With Ischemic Stroke

Adams¹,

Zoppo²,

Alberts³

et al. 2007

Circulation

1,062

745

View full text Add to dashboard Cite

show abstract

“…[739][740][741][742][743][744][745][746][747][748][749][750][751][752] A 2003 systematic review of the excitatory amino acid modulator trials found no rates of improvements in either death or favorable outcomes with treatment. 753 Lubeluzole, which is thought to downregulate the glutamate-activated nitric oxide synthase pathway, was tested in several clinical trials, including one that evaluated the combination of the medication and intravenous rtPA. 754 Although a pilot study suggested safety and a reduction in deaths, subsequent larger clinical trials found no effects in reducing deaths or improving outcomes after stroke.…”

Section: Pharmacological Agentsmentioning

confidence: 99%

Guidelines for the Early Management of Patients With Acute Ischemic Stroke

Jauch¹,

Saver²,

Adams³

et al. 2013

Stroke

5,370

1,801

View full text Add to dashboard Cite

Background and Purpose-The authors present an overview of the current evidence and management recommendations for evaluation and treatment of adults with acute ischemic stroke. The intended audiences are prehospital care providers, physicians, allied health professionals, and hospital administrators responsible for the care of acute ischemic stroke patients within the first 48 hours from stroke onset. These guidelines supersede the prior 2007 guidelines and 2009 updates. Methods-Members of the writing committee were appointed by the American Stroke Association Stroke Council's Scientific Statement Oversight Committee, representing various areas of medical expertise. Strict adherence to the American Heart Association conflict of interest policy was maintained throughout the consensus process. Panel members were assigned topics relevant to their areas of expertise, reviewed the stroke literature with emphasis on publications since the prior guidelines, and drafted recommendations in accordance with the American Heart Association Stroke Council's Level of Evidence grading algorithm. Results-The goal of these guidelines is to limit the morbidity and mortality associated with stroke. The guidelines support the overarching concept of stroke systems of care and detail aspects of stroke care from patient recognition; emergency medical services activation, transport, and triage; through the initial hours in the emergency department and stroke unit. The guideline discusses early stroke evaluation and general medical care, as well as ischemic stroke, specific interventions such as reperfusion strategies, and general physiological optimization for cerebral resuscitation. The American Heart Association makes every effort to avoid any actual or potential conflicts of interest that may arise as a result of an outside relationship or a personal, professional, or business interest of a member of the writing panel. Specifically, all members of the writing group are required to complete and submit a Disclosure Questionnaire showing all such relationships that might be perceived as real or potential conflicts of interest. Guidelines for the Early Management of PatientsThis statement was approved by the American Heart Association Science Advisory and Coordinating Committee on December 12, 2012. A copy of the document is available at http://my.americanheart.org/statements by selecting either the "By Topic" link or the "By Publication Date" link. To purchase additional reprints, call 843-216-2533 or e-mail kelle.ramsay@wolterskluwer.com.The Executive Summary is available as an online-only Data Supplement with this article at http://stroke.ahajournals.org/lookup/suppl/ doi:10.1161/STR.0b013e318284056a/-/DC1.The American Heart Association requests that this document be cited as follows: Jauch EC, Saver JL, Adams HP Jr, Bruno A, Connors JJ, Demaerschalk BM, Khatri P, McMullan PW Jr, Qureshi AI, Rosenfield K, Scott PA, Summers DR, Wang DZ, Wintermark M, Yonas H; on behalf of the American Heart Association Stroke Council, Council on Cardio...

show abstract

“…However, no clear therapeutic efficacy was observed. 21,43,44 This spectacular lack of success has led to a massive decline in drug discovery research in the area of stroke and traumatic brain injury. This may change if efficacy is observed with compounds currently in clinical trial for stroke, e.g., Cerovive (NXY-059).…”

Section: Drugs For Neurodegenerative Disordersmentioning

confidence: 99%

Drug metabolism and pharmacokinetics, the blood-brain barrier, and central nervous system drug discovery

et al. 2005

View full text Add to dashboard Cite

Summary:The worldwide market for therapies for CNS disorders is worth more than $50 billion and is set to grow substantially in the years ahead. This is because: 1) the incidence of many CNS disorders (e.g., Alzheimer's disease, stroke, and Parkinson's disease) increase exponentially after age 65 and 2) the number of people in the world over 65 is about to increase sharply because of a marked rise in fertility after World War II. However, CNS research and development are associated with significant challenges: it takes longer to get a CNS drug to market (12-16 years) compared with a non-CNS drug (10 -12 years) and there is a higher attrition rate for CNS drug candidates than for non-CNS drug candidates. This is attributable to a variety of factors, including the complexity of the brain, the liability of CNS drugs to cause CNS side effects, and the requirement of CNS drugs to cross the blood-brain barrier (BBB). This review focuses on BBB penetration, along with pharmacokinetics and drug metabolism, in the process of the discovery and development of safe and effective medicines for CNS disorders.

show abstract

Excitatory amino acid antagonists for acute stroke

Cited by 86 publications

References 68 publications

Guidelines for the Early Management of Adults With Ischemic Stroke

Guidelines for the Early Management of Adults With Ischemic Stroke

Guidelines for the Early Management of Patients With Acute Ischemic Stroke

Drug metabolism and pharmacokinetics, the blood-brain barrier, and central nervous system drug discovery

Contact Info

Product

Resources

About